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Background: Small noncoding microRNA (miRNA) have regulatory functions in
polycystic ovary syndrome (PCOS) that differ to those in women without PCOS.
However, little is known about miRNA expression in women with PCOS who are not
insulin resistant (IR).
Methods: Circulating miRNAs were measured using quantitative polymerase chain
reaction (qPCR) in 24 non-obese BMI and age matched women with PCOS and 24
control women. A miRNA data set was used to determine miRNA levels.
Results:Women with PCOS showed a higher free androgen index (FAI) and anti-mullerian
hormone (AMH) but IR did not differ. Four miRNAs (miR-1260a, miR-18b-5p, miR-424-5p,
and miR let-7b-3p) differed between control and PCOS women that passed the false
discovery rate (FDR) out of a total of 177 circulating miRNAs that were detected. MiRNA let-
7b-3p correlated with AMH in PCOS (p < 0.05). When the groups were combined, miR-
1260a correlated with FAI and let-7b-3p correlated with body mass index (BMI) (p < 0.05).
There was no correlation to androgen levels. Ingenuity pathway analysis showed that nine of
the top 10 miRNAs reported were associated with inflammatory pathways.
Conclusion:When IR did not differ between PCOS and control women, only four miRNA
differed significantly suggesting that IR may be a driver for many of the miRNA changes
reported. Let-7b-3p was related to AMH in PCOS, and to BMI as a group, whilst miR-
1260a correlated with FAI. Androgen levels, however, had no effect upon circulating
miRNA profiles. The expressed miRNAs were associated with the inflammatory pathway
involving TNF and IL6.
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Butler et al. MicroRNAs in Non-Insulin Resistant PCOSINTRODUCTION
In females of reproductive age, polycystic ovarian syndrome
(PCOS) is the leading disorder of the endocrine system, affecting
9–21% of females and PCOS is a major cause of anovulatory
infertility (1). Characteristic findings in PCOS include obesity,
type 2 diabetes, hyperandrogenism, insulin resistance (IR), and
hypercholesterolemia (2). Genetic factors, such as mutations,
and changes in epigenetics and/or expression of non-coding
RNAs, are thought to play a significant role in the etiology of
PCOS (3–5).
MiRNAs are short (transcripts are ~22 nucleotides long)
endogenous non-coding RNAs that bind (6) via their first eight
bases to messenger RNA (mRNA) transcripts, resulting in post-
transcriptional regulation of gene expression through mRNA
degradation and translational repression (7–10). MiRNAs
attenuate the expression of a multitude of target mRNAs
regulating biological and cellular pathways. It is, therefore, not
surprising that miRNAs play a role in obesity and related
conditions such as insulin resistance, glucose intolerance, type 2
diabetes and dyslipidemias (11–15).
MiRNA expression in the serum of PCOS women is therefore
likely to be complex, and studies in the literature appear
discordant (16). It is reported that miR-21, miR-27b, miR-103,
and miR-155 expression is altered in both obesity and in PCOS,
and therefore indirectly in IR (17). MiR-93 has also been
implicated in downregulating the expression of SLC2A4, an
insulin-sensitive glucose transporter, in adipose tissue (18)
where it is overexpressed in women with PCOS with insulin
resistance (19), though how this relates to the circulating miRNA
is unclear. Others have reported several tissue related miRNA to
be associated with IR (6), examples being miR-135 in endothelial
cells (20) and let7 in muscle cells (21).
It is therefore clear that miRNAs are related to insulin
resistance, but no study has been undertaken to date to
determine if miRNAs differ in a PCOS population that was not
insulin resistant compared to a control population.MATERIALS AND METHODS
Study Design
This was a prospective cohort study and was performed from
January 2014 to January 2016 within the Hull Hospitals
following approval by the Yorkshire and The Humber NRES
ethical committee, UK, and all women gave their written
informed consent. All women attending the IVF clinic for
treatment of their subfertility by means of assisted conception
were approached, of whom 60 subjects (30 PCOS and 30
controls) agreed to participate and were concurrently recruited.
Forty-eight women, 24 PCOS subjects and 24 normal controls,
aged between 20–44 years who fulfilled the criteria of not having
insulin resistance were included in the study (HOMA-IR less
than 2). For the diagnosis of PCOS, two of three diagnostic
criteria of the Rotterdam consensus were used; these criteria are
(1) clinical and biochemical hyperandrogenemia, requiring aFrontiers in Endocrinology | www.frontiersin.org 2Ferriman-Gallwey score of >8 and a free androgen index of >4
respectively, (2) oligomenorrhea or amenorrhea and (3)
polycystic ovaries seen on transvaginal ultrasound (22). Study
participants had no other condition or illness and all women
were on folic acid 400 µg daily, but no other medication. Testing
was undertaken to ensure that no patient had any of the
following endocrine conditions: non-classical 21-hydroxylase
deficiency, hyperprolactinaemia, Cushing’s disease or an
androgen-secreting tumour. Control women were age and
body mass index (BMI) matched to the PCOS patients.
Demographic data for both control and PCOS women is
shown in Table 1.
The primary endpoint was the expression of miRNA between
non-insulin resistant PCOS and age and BMI matched
control subjects.
Sample Collection
Following an overnight fast, blood samples were taken in the
follicular phase of the cycle. Serum was collected and stored
frozen at -80°C for batch analysis. Serum testosterone was
measured by isotope dilution liquid chromatography- tandem
mass spectrometry (Waters Corporation, Manchester, UK). Sex
hormone binding globulin (SHBG) was determined using an
immunometric assay (following the manufacturer-recommended
protocol), the fluorescence being detected using a DPC Immulite
2000 analyzer. The free androgen index (FAI) was calculated from
the formula: total testosterone x100/SHBG. Serum insulin was
determined by competitive chemiluminescent immunoassay using
a DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, UK)
following the manufacturer-recommended protocol with no
stated cross-reactivity with proinsulin; analytical sensitivity was 2
µU/ml and the coefficient of variation (CV) was 6%. Plasma glucose
was measured using the manufacturer-recommended protocol on a
Synchron LX 20 analyzer (Beckman-Coulter) with a CV of 1.2% at
the mean glucose concentration of 5.3mmol/liter. Insulin resistance
was calculated using the standard HOMA method [HOMA-IR =
(insulin x glucose)/22.5]. Anti-Müllerian hormone was measuredTABLE 1 | Characteristics of control and PCOS subjects showing that whilst
matched for age and body mass index, PCOS subjects had higher androgen
(free androgen index) and anti-Mullerian hormone (AMH) levels.
Control women (n = 24) PCOS women (n = 24) P-value
Mean ± SD Mean ± SD
Age (years)a 32.5 ± 4.1 31.0 ± 6.4 0.21
BMIa 24.8 ± 1.1 25.9 ± 1.8 0.26
Glucose (mmo/l)b 4.8 ± 0.4 4.7 ± 0.4 0.07
Insulin (mIU/ml)b 7.7 ± 4.2 8.3 ± 4.7 0.60
HOMA IRb 1.7 ± 1.0 1.8 ± 1.0 0.83
FAIb 1.3 ± 0.5 4.1 ± 2.9 0.001
AMH (ng/ml)b 24 ± 13 57 ± 14 0.001September 2020 | Volume 11 | ArticleBMI, body mass index; FAI, free androgen index (= testosterone/sex hormone binding
globulin x 100); HOMA-IR, homeostatic model assessment-insulin resistance). AMH,
antimullarian hormone. Anti-Müllerian hormone was measured using a Beckman Coulter
Access automated immunoassay.
aT-test used; bMann-Whitney test used.571357
Butler et al. MicroRNAs in Non-Insulin Resistant PCOSusing a Beckman Coulter Access automated immunoassay; between
run precision was <3% across the range measured (23).
MiRNA Profiling and Analysis
Total RNA was isolated from 200 µl plasma of each sample using
the miRCURY RNA Isolation Kit - Biofluids (Exiqon; acquired by
Qiagen) following the manufacturer-recommended protocol. An
on-column DNase digestion was performed for 15 min during the
RNA extraction procedure based on manufacturer guidelines to
remove contaminating DNA. Since precise estimation of RNA
concentration from biofluids such as plasma is difficult (24),
reverse transcription was performed with equal volumes of RNA
from each sample (4 µl of RNA in 20 µl reverse transcription
reaction volume) using Exiqon Universal cDNA Synthesis Kit II
following the manufacturer’s protocol. Such a method of inputting
equal volumes of total RNA into the cDNA synthesis reaction has
been described earlier (25). RNA integrity and reverse transcription
efficiency were assessed using representative samples that were
loaded on to miRNA QC PCR Panel (Exiqon). Quality control
was ensured by monitoring diagnostic assays for miRNAs that are
expressed in various tissues and present on the QC panel.
Additionally, the QC panel also contains assays for the synthetic
RNA isolation spike-ins, UniSp2, 4 and 5 (Exiqon), that were added
prior to RNA isolation and the cDNA synthesis spike-ins, UniSP6
and cel-miR-39-3p (Exiqon), added prior to reverse transcription.
To perform qPCR, 2x Exilent SYBRGreenmaster mix (Exiqon) was
mixed with fifty-fold diluted cDNA and 4 ml per 2 ml ROX
Reference Dye (ThermoFisher Scientific) before loading on to
Exiqon Serum/Plasma Focus microRNA PCR Panel, 384 well
(V4.M). The Exiqon Serum/Plasma Focus microRNA PCR Panel
used for miRNA profiling in this study contains primer sets for 179
circulating miRNAs in addition to assays for synthetic spike-ins and
reference miRNAs. Amplification was performed using
QuantStudio 12K Flex Real-Time PCR System (ThermoFisher
Scientific) followed by pre-processing of raw data and statistical
analysis using GenEx qPCR analysis software, version 6 (MultiD).
Pre-processing of the raw data was conducted as follows. Inter-
panel differences among runs were normalized with the UniSp3
spike-in contained on the panels. False positive amplifications were
eliminated by running a no-template negative control panel and
then setting a DCt of 1 between the sample and negative control for
every miRNA assayed. To identify and leave out haemolysed
samples, a DCt >7 between hsa-miR-23a-3p and hsa-miR-451a
was set as a cutoff as described (26, 27). Data was normalized against
the global mean of all expressed miRNAs with a Ct less than 35.
Upon completion of pre-processing, samples were divided into two
groups for statistical analysis, PCOS, and controls.
Ingenuity Pathway Analysis
Ingenuity Pathways Analysis (Qiagen, Redwood City, USA) was
undertaken on the miRNA data. IPA is a web-based bioinformatics
application in which the miRNA data is upload and that then
generates lists of genes and allows interactive building of networks
to represent biological systems. Pathways overrepresented by the
FDR-significant miRNA changes at q<0.05 (28) were identified.Frontiers in Endocrinology | www.frontiersin.org 3Statistics
No data on PCOS without insulin resistance and miRNA
expression were available to undertake a formal power analysis
on changes in miRNA expression levels; therefore, this study was
conducted as a pilot study. Birkett and Day (29) have suggested a
minimum of 20 degrees-of-freedom to allow an estimation of
variance from which a larger trial could be powered; therefore, in
this study, 24 subjects in each group were recruited. Statistical
analysis was calculated using SPSS (v22, Chicago, Illinois). Data
presentation: for continuous data, the descriptive data is here
presented as mean ± SD. Students t-test was used to compare
between means; Mann Whitney tests were used for data that
violated the assumptions of normality when tested using the
Kolmogorov-Smirnov test. Spearman’s correlation test was used
to assess associations. An unpaired two-tailed t-test with
Bonferroni correction was used in order to test any paired
changes in miRNA expression levels between the PCOS and
control women. False discovery rates (FDR) of q<0.05 (28) were
taken as significant.RESULTS
Baseline data for the 24 PCOS patients and the 24 control
patients are shown in Table 1, where it can be seen that the
subjects were non-obese, matched for age and BMI, and were not
insulin resistant.
Four miRNAs passed the false discovery rate (FDR) and differed
between the PCOS subjects and controls, as shown in Table 2 and
Figure 1. A total of 177 circulating miRNAs were detected (shown
in Supplemental Table 1); the 4 miRNA that passed FDR p<0.05
that differed between normal women and PCOS were miR-1260a
(p = 0.015), miR-18b-5p (p = 0.029), miR-424-5p (p = 0.038), and
let-7b-3p (p = 0.042). Table 3 shows the correlation of the
demographic features with the miRNAs. Let-7b-3p correlated
with AMH in PCOS (p < 0.05), and when the groups were
combined miR-1260a correlated with free androgen index (FAI)
and AMH; let-7b-3p correlated with BMI (p < 0.05).TABLE 2 | Top 10 miRNA detected, four of which differed significantly between
patients with and without PCOS matched for age and BMI.










hsa-miR-133b 1.730 0.113September 2020 | VoPositive fold change indicates that the miRNA is upregulated in PCOS women compared
to controls. Negative fold change indicates that the miRNA is downregulated in PCOS
women compared to controls.lume 11 | Article 571357
Butler et al. MicroRNAs in Non-Insulin Resistant PCOSIt has been shown recently that differing noncoding RNA can
act in a coordinated manner to form a regulatory noncoding
RNA network interacting with other noncoding RNAs, such as
microRNA and circularRNA that may then effect multiple
downstream biological processes (30). Therefore, Ingenuity
Pathway Analysis was undertaken for the top 10 miRNAs
determined here. As shown in Figure 2, nine of the top 10
miRNAs showed functional connectivity as part of the regulatory
network of genes involved in the pathway associated with
inflammation and these included miR-1260a, miR-18b-5p,Frontiers in Endocrinology | www.frontiersin.org 4miR-424-5p, let-7b-3p, miR-2110, let-7c-5p, miR-130a-3p,
miR-150-5p, and miR-133b; however, CRP as a marker of
inflammation did not differ between groups (Table 1).DISCUSSION
In this non-obese, non-insulin resistant cohort of women with
PCOS, four miRNAs showed significantly altered expression
compared to the control women: miR-1260a, miR-18b-5p,FIGURE 1 | Volcano plot of fold changes in the key miRNAs that passed the FDR threshold and significance level.TABLE 3 | Spearman correlations of demographics with top four significant miRNAs for both control and PCOS patients, control and PCOS patients alone.
Age BMI AMH Fertility rate HOMA-IR FAI
All patients
hsa-let-7b-3p -0.148 0.261* -0.159 0.142 -0.094 -0.090
hsa-miR-1260a -0.110 -0.041 -0.349** -0.143 -0.161 -0.331*
hsa-miR-424-5p -0.220 0.143 0.100 0.049 -0.114 0.140
hsa-miR-18b-5p -0.044 0.110 -0.195 0.026 -0.185 -0.093
Control patients
hsa-let-7b-3p -0.311 0.392* 0.052 0.233 -0.137 0.018
hsa-miR-1260a -0.179 0.116 -0.153 0.029 -0.116 -0.203
hsa-miR-424-5p -0.295 0.225 -0.048 0.095 -0.223 -0.103
hsa-miR-18b-5p -0.218 0.276 -0.191 0.122 -0.225 -0.091
PCOS patients
hsa-let-7b-3p 0.041 0.113 -0.408* -0.015 -0.038 -0.063
hsa-miR-1260a -0.208 -0.152 -0.212 -0.330 -0.158 -0.263
hsa-miR-424-5p -0.057 -0.002 -0.044 -0.169 -0.075 0.130
hsa-miR-18b-5p 0.192 -0.131 -0.348 -0.191 -0.179 -0.129September 2020 | Volume 11 | ArticleBMI, body mass index; AMH, antimullerian Hormone; HOMA-IR, homeostatic model assessment-insulin resistance; FAI, free androgen index.
*P-value < 0.05; **P-value < 0.001.571357
Butler et al. MicroRNAs in Non-Insulin Resistant PCOSmiR-424-5p, and let-7b-3p. When obesity and insulin resistance
are taken into account, it is likely that these four miRNA are
specifically related to PCOS. Further, it is of interest that let-7b-
3p correlated with AMH in PCOS women, as AMH has been
suggested as a biomarker of PCOS though of low sensitivity (31,
32). When weight matched obese PCOS and control women are
compared, the number of miRNA that differ between groups are
much fewer than those previously reported in the literature (33),
and none of the miRNA reported for that obese cohort differed in
this study. As expected, several of the miRNA found in the obese
study previously reported were associated with insulin resistance
(34) whilst the four miRNA described here were not.
The strength of this study was the homogenous control and
PCOS populations studied; however, this was a selected PCOS
population that may not be generalizable. In addition, this pilot
study was limited by having a small number of subjects, yet
clearly showed that miRNAs do differ between PCOS and control
women when age, BMI and insulin resistance are accounted for.
However, functional studies are required to determine the role of
each of the miRNA reported here.
In this study, analysis of the combined PCOS and control
women revealed that miR-1260a correlated with FAI and AMH,
but this correlation was not found in obesity with insulin
resistance (33). It is reported that miR-1260a is associated with
type 2 diabetes (35) as is miR-424 (36), whilst miR-let 7 has been
associated with a reduction in insulin signaling (36). MiR-let-7b-3pFrontiers in Endocrinology | www.frontiersin.org 5correlated with BMI for these normal weight subjects, a correlation
that appeared to be lost in obese subjects (33).
Recent evidence indicates that long-noncoding RNA, circular
RNA and microRNA may act together as a functional regulatory
network (30) and therefore the function of an individual miRNA
may not be evident. In addition, with so few studies to date,
individual microRNA may not obviously map its function to the
disease process under study. This may be seen here for the
miRNAs that differed between the women with and without
PCOS: miR-1260a has been reported to be associated with
prostate and lung cancer and aortic aneurysms (37–39);
similarly, miR-18b-5p has been associated with oncogenic
activity (40). MiR-424-5p may stimulate an immune effect
through the mTOR pathway (41) and it has been shown that
mTOR signaling was responsible for excessive follicle activation
and growth in an animal model of PCOS (42). Let-7b-3p has
been associated with several malignancies including melanoma,
lung cancer and ovarian serous carcinoma (genecards.org).
The Ingenuity Pathway Analysis revealed that nine of the top
10 miRNA identified here showed functional connectivity as part
of a regulatory network of genes predominantly associated with
central regulators of inflammation through tumour necrosis
factor (TNF) and interleukin 6 (IL6), though serum levels of
both have been reported not to differ between PCOS and control
women (43). Of note, CRP as a marker of inflammation did not
differ between groups in this study. It has been suggested thatFIGURE 2 | Pathway connections for the inflammatory pathways for the top 10 miRNAs showing nine were associated with the pathway relating to tumor necrosis
factor and interleukin 6.September 2020 | Volume 11 | Article 571357
Butler et al. MicroRNAs in Non-Insulin Resistant PCOSchronic low grade inflammation may mediate the effect of
sympathetic dysfunction on hyperandrogenism and insulin
resistance (44).
Our findings are discrepant to others where serum miR-21
(45) and miR-6767-5p (46) are elevated, whilst miR-320 is
lowered in PCOS (47); the likely explanation for this is that
these miR are associated with an increased BMI (48). As noted
above, miR-93 and miR-223 may play a role in insulin resistance
(19) and did not differ in this study, likely because insulin
resistance did not differ between the PCOS and control women.
This study indirectly supports the concept that PCOS women are
characterized by different phenotypes: one hyperandrogenic (women
included in this study) and the other hyperinsulinemic with insulin
resistance (excluded in this study) (49). Therefore, the miRNA
expression may significantly differ between these two phenotypes
corroborating that the pathogenetic pathway could be different and
therefore subjects may respond differently to treatment (50–52).
These results may be generalisable to a Caucasian population
of non-insulin resistant women with PCOS, but clarification is
needed to determine if there are ethnic differences as seen for
other metabolic parameters (53).
In conclusion, only four of the 177 miRNAs expressed differed
significantly in non- insulin resistant women with and without PCOS
when age and BMI were matched. Let-7b-3p was related to AMH in
PCOS, and to BMI as a group, whilst miR-1260a correlated with FAI.
Nine of the 10 expressed miRNAs showed functional connectivity
with the inflammatory pathway involving TNF and IL6.DATA AVAILABILITY STATEMENT
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